Healthcare Services

Gastric Ulcers Market Outlook 2026–2030 Exploring New Business Opportunities

April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Gastric Ulcers Market During 2026–2030?

The gastric ulcers market has shown significant expansion in recent years. Its valuation is projected to increase from $4.53 billion in 2025 to $4.78 billion in 2026, advancing at a compound annual growth rate (CAGR) of 5.5%. The historical growth of this market can be attributed to the prevalence of h pylori infection, the widespread use of antacids, the availability of antibiotics, the provision of hospital-based GI treatments, and the adoption of endoscopic diagnosis.

The gastric ulcers market size is projected to observe consistent expansion over the coming years. Its valuation is expected to ascend to $5.78 billion by 2030, achieving a compound annual growth rate (CAGR) of 4.9%. This anticipated growth during the forecast period is propelled by factors such as the creation of advanced acid-suppression drugs, the necessity for sustained ulcer management, an increase in outpatient care provisions, enhancements in diagnostic technologies, and a surge in lifestyle-associated disorders. Prominent trends expected within this period encompass a greater adoption of proton pump inhibitors, an elevated emphasis on eradicating Helicobacter pylori, an expansion in combination drug treatments, the wider application of non-invasive diagnostic techniques, and heightened public understanding of gastrointestinal ailments.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17160&type=smp

What Underlying Factors Are Accelerating The Growth Of The Gastric Ulcers Market?

The expanding geriatric population is set to boost the gastric ulcers market’s progression. This demographic refers to individuals typically aged 65 years and older, who often face specific health considerations linked to aging. The growth in the older population stems from advancements in healthcare, which contribute to longer life expectancies, alongside declining birth rates observed in many global regions. Gastric ulcers are prevalent among the geriatric population, mainly due to increased NSAID usage and diminished mucosal protection, which frequently raises the risk of complications. For instance, in January 2024, data from the Population Reference Bureau (PRB), a US-based private non-profit organization, indicated that the number of Americans aged 65 and older is projected to increase from 58 million in 2022 to 82 million by 2050, marking a 47% rise. Furthermore, this age group’s proportion of the total population is expected to climb from 17% to 23%. This transformation points to a significant aging trend within the U.S. population. Such projections underscore the escalating importance of addressing the needs of older adults across various sectors. Thus, the increasing geriatric population is a key driver for the growth of the gastric ulcers market.

How Are The Various Segments Of The Gastric Ulcers Market Categorized?

The gastric ulcers market covered in this report is segmented –

1) By Drug Class: Proton Pump Inhibitors (PPI), H2 Antagonists, Antacids, Antibiotics, Cytoprotective Agents, Other Drug Classes

2) By Diagnosis: Stool Test, Endoscopy, Imaging Tests, Computed Tomography (CT) Scan, X-ray, Blood Tests, Other Diagnosis

3) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegments:

1) By Proton Pump Inhibitors (PPI): Omeprazole, Lansoprazole, Pantoprazole, Esomeprazole, Rabeprazole

2) By H2 Antagonists: Ranitidine, Famotidine, Cimetidine, Nizatidine

3) By Antacids: Calcium Carbonate, Magnesium Hydroxide, Aluminum Hydroxide, Sodium Bicarbonate

4) By Antibiotics: Amoxicillin, Clarithromycin, Metronidazole, Tetracycline

5) By Cytoprotective Agents: Sucralfate, Misoprostol, Bismuth Subsalicylate

6) By Other Drug Classes: Prostaglandin Analogues, Prokinetic Agents, Herbal And Alternative Medications, Combination Therapies

How Are Trends Transforming The Gastric Ulcers Market Landscape?

Leading companies operating in the gastric ulcer market are prioritizing the development of innovative products, such as advanced drug formulations, to enhance treatment efficacy and minimize adverse reactions. New formulation drugs are defined as medications designed with novel combinations of active ingredients, delivery systems, or dosage forms to improve their effectiveness, safety, and patient compliance. For example, in June 2024, Akums Drugs and Pharmaceuticals Ltd., an India-based pharmaceutical preparation manufacturing company, launched Rabeprazole + Levosulpiride SR Capsules, aiming to provide improved relief for conditions like gastro-oesophageal reflux disease (GERD) and various gastrointestinal tract (GIT) disorders. These specific products combine a proton pump inhibitor and a prokinetic agent, effectively treating gastrointestinal disorders such as gastroesophageal reflux disease (GERD) and gastric ulcers. This formulation not only reduces gastric acid secretion but also improves gastric motility, offering comprehensive relief from symptoms like heartburn and indigestion.

Which Major Firms Influence Developments In The Gastric Ulcers Market?

Major companies operating in the gastric ulcers market are Pfizer Inc., Merck & Co Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Co. Ltd, Boehringer Ingelheim, Viatris Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd, Cadila Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Yuhan Corporation, Daewoong Pharmaceutical Co. Ltd, Cadila Healthcare Ltd, Novitium Pharma LLC

Read the full gastric ulcers market report here:

https://www.thebusinessresearchcompany.com/report/gastric-ulcers-global-market-report

Which Region Is Projected To Dominate The Gastric Ulcers Market During The Forecast Period?

North America was the largest region in the gastric ulcers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric ulcers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Gastric Ulcers Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=17160&type=smp

Browse Through More Reports Similar to the Global Gastric Ulcers Market 2026, By The Business Research Company

Gastric Cancer Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Gastric Ulcers Global Market Report

https://www.thebusinessresearchcompany.com/report/gastric-ulcers-global-market-report

Esophageal Cancer Global Market Report

https://www.thebusinessresearchcompany.com/report/esophageal-cancer-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795